Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
messenger RNA (alpha-synuclein) is a preclinical mRNA-based in vivo gene editing candidate being developed by Factor Biosciences Therapeutics for the treatment of Parkinson's disease. The therapy utilizes Factor's proprietary mRNA technology to deliver gene-editing components directly to cells in vivo, specifically targeting the alpha-synuclein (SNCA) gene or its regulatory pathways. By reducing the production or accumulation of alpha-synuclein protein aggregates, which are central to the pathogenesis of Parkinson's and other synucleinopathies, the drug aims to modify the course of the disease rather than just managing symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on messenger RNA (alpha-synuclein).